# QLC5508

Source: https://onco.cc/drugs/qlc5508/  
OnCo record `qlc5508` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

QLC5508 is an experimental antibody-drug conjugate from Qilu Pharmaceutical in phase 3 trials for oesophageal cancer, prostate cancer and non-small-cell lung cancer, aimed at B7-H3.

## Summary

QLC5508 (MHB088C) is an antibody-drug conjugate developed by Qilu Pharmaceutical and Minghui Pharmaceutical (Hangzhou). Its target is B7-H3. ClinicalTrials.gov describes the intervention as: B7H3 ADC; QLC5508 will be administered by injection at the dose and dosing frequency specified in the protocol. It is the investigational product in 6 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT07463573 (QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Oesophageal Squamous Cell Carcinoma) and NCT06954246 (A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer), in oesophageal cancer, prostate cancer and non-small-cell lung cancer. The largest, NCT07102004, plans to enrol 515 participants with primary completion was scheduled for 2026-07 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Code: MHB088C
- Modality: ADC
- Mechanism: Antibody-drug conjugate directed at B7-H3, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.

## Sources

- ClinicalTrials.gov: trials of QLC5508: https://clinicaltrials.gov/search?intr=MHB088C

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- targets: [B7-H3](https://onco.cc/targets/b7h3/)
- companies: [Minghui Pharmaceutical](https://onco.cc/companies/minghui-pharmaceutical/), [Qilu Pharmaceutical](https://onco.cc/companies/qilu-pharmaceutical/)
- trials: [A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer](https://onco.cc/trials/nct07198633/), [A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Sm](https://onco.cc/trials/nct07802821/), [A Study of MHB088C Combined With MHB039A in Patients With Advanced Malignant Solid Tumors](https://onco.cc/trials/nct07126665/), [A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer](https://onco.cc/trials/nct06954246/), [A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct07256782/), [QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma](https://onco.cc/trials/nct07463573/), [Study of MHB088C for Patients With Advanced Solid Malignant Tumors](https://onco.cc/trials/nct07102004/)

---
JSON: https://onco.cc/api/v1/entities/qlc5508.json